FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as ocean freight forwarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, D.C. 20573.

Atlantic Overseas Express Inc., 2550 NW 72 Avenue, Suite 100, Miami, FL 33122, Officers: Jorge E. Gomez, President, Lourdes Leon, Vice President

Dated: June 17, 1998.

Joseph C. Polking,

Secretary.

[FR Doc. 98–16631 Filed 6–22–98; 8:45 am]

BILLING CODE 6730–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Office of the Secretary, DHHS.

ACTION: Notice of meeting.

The Advisory Committee on Blood Safety and Availability will meet on August 27, 1998, from 8:00 am to 5:00 pm and on August 28, 1998 from 8:00 am to 3:00 pm. The meeting will take place in the Ticonderoga Room of the Hyatt Regency Hotel on Capitol Hill, 400 New Jersey, NW., Washington, DC. 2001. The meeting will be entirely open to the public.

The Committee will consider potential barriers to the evolution from human- to recombinant-based blood products. On August 27, 1998 the committee will review information presented to it by representatives of consumers, industry and government agencies. At the conclusion of these presentations, the public will be invited to comment. Following these presentations, the Committee will consider what, if any, recommendations to make to the Department on this matter.

Prospective speakers should notify the Executive Secretary of their desire to address the Committee and should plan for no more than 5 minutes of comment.

An attempt will be made to schedule future meetings of the Advisory Committee on Blood Safety and Availability on the last Thursday and Friday of January, April and August in 1999.

FOR FURTHER INFORMATION CONTACT: Stephen D. Nightingale, M.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Safety, Department of Health and Human Services, 200 Independence Avenue, SW., Washington, DC 20201. Phone (202) 690–5560 FAX (202) 690–6584 e-mail SNIGHTIN@osophs.dhhs.gov.

Dated: June 15, 1998.

Stephen D. Nightingale, MD.,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. 98–16604 Filed 6–22–98; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Agency Information Collection Under OMB Review

Title: Information Collection from applicants who will respond to Request for Applications for funding of 6 OCS competitive grants.

OMB No.: 0970–0062.

Description: The Office of Community Services is requesting approval to continue the use of its program announcements to collect information which will enable the agency to determine which projects to fund and the amount of the grant awards. The programs covered include: Community Food and Nutrition; Discretionary Grants Program; Low Income Home Energy Assistance Program; Job Opportunities for Low-Income Individuals; Training and Technical Assistance and Capacity Building; and Family Violence Prevention and Services Program.

Information collected from the requirements contained in these 6 program announcements will be the sole source of information available to OCS in reviewing applications leading to awards of discretionary grants to eligible applicants.

The applications forms that will be used contain information for competitive review in accordance with the program announcements' guidelines. The data provided is necessary to compute the amount of the grant in relation to proposed project activities by the ACF Grant Officers.

OMB recommended that ACF submit one information collection package covering all OCS program announcements, since the same application form is used in each announcement. This information collection was last approved in 1995 and is due to expire September 30, 1998. Since the last approval, the Demonstration Partnership Program no longer exists. Therefore, this request covers 6 programs, rather than the 7 programs previously covered.

Respondents: Not-for-profit institutions.

Instrument	Estimated number of respondents	Number of responses per respondent	Average burden hours per	Total burden hours
CFN Announcement	250	1	10	2500
LIHEAP Announcement	10	1	24	240
Community Economic Dev. Announcement	200	1	35	7000
JOLI Announcement	150	1	40	6000
CSBG T&TA Announcement	25	1	24	600
Family Violence Announcement	100	1	40	4000

Estimated Total Annual Burden: 20,340.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW,

Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: June 17, 1998.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 98–16627 Filed 6–22–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F–0436]

Asahi Denka Kogyo K.K.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Asahi Denka Kogyo K.K. has filed a petition proposing that the food additive regulations be amended to provide for the expanded safe use of 2,2′-methylenebis(4,6-di-*tert*-butylphenyl)2-ethylhexyl phosphite as an antioxidant and/or stabilizer in high density polyethylene articles intended for contact with food.

FOR FURTHER INFORMATION CONTACT: Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–15), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3095.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 8B4599) has been filed by Asahi Denka Kogyo K.K., c/o Japan Technical Information Center, Inc., 775 S. 23d St., Arlington, VA 22202. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the expanded safe use of 2,2′-methylenebis(4,6-di-*tert*-butylphenyl)2-ethylhexyl phosphite as an antioxidant and/or stabilizer in high density polyethylene articles intended for contact with food.

The agency has determined under 21 CFR 25.32(i) that this action is of the type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: June 11, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–16622 Filed 6–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 77N–0240]

Erythrityl Tetranitrate; Drug Efficacy Study Implementation; Revocation of Exemption; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is revoking the temporary exemption that has allowed single-entity coronary vasodilator drug products containing erythrityl tetranitrate to remain on the market beyond the time limits scheduled for implementation of the Drug Efficacy Study. FDA is announcing that the products lack substantial evidence of effectiveness and is offering an opportunity for a hearing on a proposal to withdraw approval of any applicable new drug applications (NDA's) or abbreviated new drug applications (ANDA's).

DATES: The revocation of exemption is effective June 23, 1998; requests for hearings are due on or before July 23, 1998; data in support of hearing requests are due on or before August 24, 1998.

ADDRESSES: Communications in response to this notice should be identified with the reference number DESI 1786 and directed to the attention of the appropriate office named below.

A request for a hearing, supporting data, and other comments are to be identified with Docket No. 77N–0240 and submitted to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

A request for an opinion on applicability of this notice to a specific product should be directed to the Division of Prescription Drug Compliance and Surveillance (HFD–330), Center for Drug Evaluation and Research, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

FOR FURTHER INFORMATION CONTACT: Mary E. Catchings, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

Under the agency's Drug Efficacy Study Implementation (DESI) program, the National Academy of Sciences/National Research Council (NAS/NRC) evaluated the effectiveness of certain coronary vasodilators. Based on NAS/NRC's recommendations, FDA classified the coronary vasodilators as probably and possibly effective for indications relating to the management, prophylaxis, or treatment of anginal attacks. This classification was announced in the **Federal Register** of February 25, 1972 (37 FR 4001).

In a notice published in the **Federal Register** of December 14, 1972 (37 FR 26623), as amended July 11, 1973 (38 FR 18477), August 26, 1977 (42 FR 43127), October 21, 1977 (42 FR 56156), and September 15, 1978 (43 FR 41282), FDA temporarily exempted the single-entity coronary vasodilators covered by the DESI program from the time limits established for completing the program (Paragraph XIV, Category I exemption). FDA granted this exemption to allow manufacturers additional time to conduct clinical studies to determine effectiveness of the drugs for prevention of anginal attacks. In the August 26, 1977, notice, FDA added certain dosage forms of erythrityl tetranitrate (not included in the Drug Efficacy Study but regarded as related drugs) to the Paragraph XIV, Category I exemption.

The exemption notices established conditions for marketing the single-entity coronary vasodilators pending FDA's conclusions about the products. FDA required that each manufacturer conduct bioavailability studies on its own product(s) and that at least one manufacturer conduct clinical effectiveness studies for each chemical entity to which the same effectiveness conclusions would ultimately apply. An